Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment/Experiment 2
From BugSigDB
Needs review
Subjects
- Location of subjects
- France
- Host species Species from which microbiome was sampled. Contact us to have more species added.
- Homo sapiens
- Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
- Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- Tumor stage tumour stage,Tumor stage,tumor stage
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Post-CT Stage I
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Post-CT Stage II/III
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Breast cancer patients after chemotherapy with TNM Stage II/III
- Group 0 sample size Number of subjects in the control (unexposed) group
- 14
- Group 1 sample size Number of subjects in the case (exposed) group
- 20
- Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
- None
Lab analysis
- Sequencing type
- WMS
- 16S variable region One or more hypervariable region(s) of the bacterial 16S gene
- Not specified
- Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
- Ion Torrent
Statistical Analysis
- Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
- relative abundances
- Statistical test
- PLS-DA (Partial least square discriminant analysis)
- Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
- 0.05
- MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
- Yes
Signature 1
Needs review
Source: Fig. 1E
Description: Variable importance plot (VIP) scores obtained within partial least square discriminant analysis describing the most discriminant species in Post-CT TNM stage I (orange) compared to Post-CT TNM stage II-III (blue)
Abundance in Group 1: increased abundance in Post-CT Stage II/III
Revision editor(s): Scholastica
Signature 2
Needs review
Source: Fig. 1E
Description: Variable importance plot (VIP) scores obtained within partial least square discriminant analysis describing the most discriminant species in Post-CT TNM stage I (orange) compared to Post-CT TNM stage II-III (blue)
Abundance in Group 1: decreased abundance in Post-CT Stage II/III
Revision editor(s): Scholastica
